Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + nivolumab vs nivolumab alone in locally advanced cervical cancer
2024-514032-25-00Phase 2Authorised
- Sponsor
- Arcagy-Gineco
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Cervical Cancer (CC), cervical squamous cell carcinoma (CSCC) and Adenosquamous Cervical Cancer (ASC) comparing Relatlimab + nivolumab with Nivolumab alone (2 arms). Planned start Sep 2024; status: authorised.
02
Drugs
relatlimabnivolumab
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)Adenosquamous Cervical Cancer (ASC)
Beyond the preview
Go deeper on 2024-514032-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514032-25-00.